Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

BACKGROUND: NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles of Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized NET. The present study evaluates the outcome of further PRRT cycles in the so called salvage setting in patients after initial response...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Main Authors: Rudisile, S., Gosewisch, A., Wenter, V., Unterrainer, M., Böning, G., Gildehaus, F. J., Fendler, W. P., Auernhammer, C. J., Spitzweg, C., Bartenstein, P., Todica, A., Ilhan, H.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6686531/
https://ncbi.nlm.nih.gov/pubmed/31395036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6000-y
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares